# AstraZeneca Alexion’s Ultomiris approved in Europe for gMG

- Link: https://www.directorstalkinterviews.com/astrazeneca-alexions-ultomiris-approved-in-europe-for-gmg/4121083411
- Published: 2022-09-23T07:53:53+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced that _Ultomiris_ (ravulizumab) has been approved in Europe as an add-
on to standard therapy for the treatment of adult patients with generalised myasthenia
gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

This decision marks the first and only approval for a long-acting C5 complement 
inhibitor for the treatment of gMG in Europe. gMG is a rare, debilitating, chronic,
autoimmune neuromuscular disease that leads to a loss of muscle function and severe
weakness.^(1) The diagnosed prevalence of gMG in the EU is estimated at approximately
89,000.^(2-8)

The approval by the European Commission follows the positive opinion of the Committee
for Medicinal Products for Human Use and is based on results from the CHAMPION-MG
Phase III trial, which were published online in _NEJM Evidence_. In the trial, _Ultomiris_
was superior to placebo in the primary endpoint of change from baseline in the Myasthenia
Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26, a patient-
reported scale that assesses patients’ abilities to perform daily activities.^(9)
Additionally, in prolonged follow-up results from the open-label extension, clinical
benefit of _Ultomiris_ was observed through 60 weeks.^(9)

> **Renato Mantegazza, Professor at the Department of Neuroimmunology and Neuromuscular
> Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, and
> CHAMPION-MG trial investigator, said**: “As physicians, we see first-hand how 
> gMG can have a debilitating impact on quality of life. Today’s approval is a major
> advancement for treating gMG in Europe, offering patients and physicians a new,
> long-acting treatment option which has shown reliable efficacy and sustained improvements
> in activities of daily living.”

> **Marc Dunoyer, Chief Executive Officer, Alexion, said**: “This approval in Europe
> of the first and only long-acting C5 inhibitor is an important step towards realising
> our vision of improving the lives of people living with gMG and increasing access
> to _Ultomiris_ worldwide. Alexion’s pioneering leadership in complement science
> has affirmed C5 inhibition as a proven approach for managing this debilitating
> disease. We’re proud to offer a new treatment option that provides more convenience
> in dosing and has shown clinical benefit in a broader range of patients, including
> those who remain symptomatic despite their initial standard of care treatment.”

In CHAMPION-MG, the safety profile of _Ultomiris_ was comparable to placebo and 
consistent with that observed in Phase III trials of _Ultomiris_ in paroxysmal nocturnal
haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS). The most 
common adverse reactions in patients receiving _Ultomiris_ were diarrhoea, upper
respiratory tract infection, nasopharyngitis and headache.^(9)

_Ultomiris_ was approved in the US in April 2022 and Japan in August 2022 for certain
adults with gMG. Regulatory reviews are ongoing in additional countries.

**_Ultomiris_**

_Ultomiris_ (ravulizumab), the first and only long-acting C5 complement inhibitor,
offers immediate, complete and sustained complement inhibition. The medication works
by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s
immune system. When activated in an uncontrolled manner, the complement cascade 
over-responds, leading the body to attack its own healthy cells. _Ultomiris_ is 
administered intravenously every eight weeks in adult patients, following a loading
dose. 

_Ultomiris_ is approved in the US, EU and Japan for the treatment of certain adults
with gMG.

_Ultomiris_ is also approved in the US, EU and Japan for the treatment of certain
adults with PNH and for certain children with PNH in the US and EU. 

Additionally, _Ultomiris_ is approved in the US, EU and Japan for certain adults
and children with aHUS to inhibit complement-mediated thrombotic microangiopathy.

As part of a broad development programme, _Ultomiris_ is being assessed for the 
treatment of additional haematology and neurology indications.

**Alexion**

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare
diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc.
As a leader in rare diseases for nearly 30 years, Alexion is focused on serving 
patients and families affected by rare diseases and devastating conditions through
the discovery, development, and commercialisation of life-changing medicines. Alexion
focuses its research efforts on novel molecules and targets in the complement cascade
and its development efforts on haematology, nephrology, neurology, metabolic disorders,
cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has
offices around the globe and serves patients in more than 50 countries.

Share on:
